Pharmacyte Biotech, Inc. (PMCB) — 10-Q Filings

10-Q Filings (6)

• PharmaCyte Swings to $15.8M Loss Amidst Warrant Revaluation, FDA Hold — Dec 18, 2025 Risk: high
  PharmaCyte Biotech, Inc. (PMCB) reported a significant net loss of $15,778,071 for the six months ended October 31, 2025, a stark contrast to the net income of
• PharmaCyte Swings to $8.4M Loss Amid FDA Hold, Strategic Review — Sep 15, 2025 Risk: high
  PharmaCyte Biotech, Inc. (PMCB) reported a net loss of $8,360,096 for the three months ended July 31, 2025, a significant decline from the net income of $23,421
• PharmaCyte Biotech Files Q3 10-Q — Mar 17, 2025 Risk: medium
  PharmaCyte Biotech, Inc. filed its 10-Q for the period ending January 31, 2025. The company, previously known as NuVilex, Inc., is in the biological products se
• PharmaCyte Biotech Files 10-Q for October 2024 — Dec 13, 2024 Risk: medium
  PharmaCyte Biotech, Inc. filed its 10-Q for the period ending October 31, 2024. The company reported financial results and provided updates on its business oper
• PharmaCyte Biotech Files 10-Q for July 2024 — Sep 17, 2024 Risk: medium
  PharmaCyte Biotech, Inc. filed its 10-Q for the period ending July 31, 2024. The company, formerly known as Nuvilex, Inc., is focused on biological products. It
• PharmaCyte Biotech, Inc. Files 10-Q for Period Ending January 31, 2024 — Mar 18, 2024 Risk: low
  PharmaCyte Biotech, Inc. (PMCB) filed a Quarterly Report (10-Q) with the SEC on March 18, 2024. PharmaCyte Biotech, Inc. filed a 10-Q report for the period endi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX